廣告
香港股市 已收市
  • 恒指

    16,541.42
    +148.58 (+0.91%)
     
  • 國指

    5,810.79
    +82.66 (+1.44%)
     
  • 上證綜指

    3,010.66
    +17.52 (+0.59%)
     
  • 道指

    39,760.08
    +477.75 (+1.22%)
     
  • 標普 500

    5,248.49
    +44.91 (+0.86%)
     
  • 納指

    16,399.52
    +83.82 (+0.51%)
     
  • Vix指數

    12.99
    +0.21 (+1.64%)
     
  • 富時100

    7,964.37
    +32.39 (+0.41%)
     
  • 紐約期油

    81.67
    +0.32 (+0.39%)
     
  • 金價

    2,216.30
    +3.60 (+0.16%)
     
  • 美元

    7.8231
    +0.0001 (+0.00%)
     
  • 人民幣

    0.9236
    +0.0004 (+0.04%)
     
  • 日圓

    0.0514
    -0.0001 (-0.12%)
     
  • 歐元

    8.4338
    -0.0354 (-0.42%)
     
  • Bitcoin

    70,653.82
    +891.44 (+1.28%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says

  • Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) has announced positive topline results from the pivotal Phase 3 MAESTRO-NASH biopsy trial of resmetirom.

  • JMP has raised the price target from $182 to $312 and reiterates its Market Outperform rating.

  • Resmetirom looks approvable based on Phase 3 MAESTRO-NASH data, the analyst said.

  • The analyst raised POS for resmetirom to 90% in both the U.S. and EU (from 70% and 60%, respectively) with peak sales of ~$5 billion and ~$1.5 billion (compared to $3 billion and ~$600 million expected earlier).

  • JMP models at an annual price of $15K in the U.S. (up from $5K) to be more in line with the annual WAC for obesity drug Wegovy ($16,188) from Novo Nordisk A/S (NYSE: NVO).

  • The analyst also raised the European price estimate to $5K (from $3,500).

  • JMP writes that Madrigal has now become a top M&A target. There is no shortage of large players with NASH exposure, including Novo Nordisk, Novartis AG (NYSE: NVS), Pfizer Inc (NYSE: PFE), Eli Lilly And Co (NYSE: LLY), Merck & Co Inc (NYSE: MRK), AstraZeneca Plc (NASDAQ: AZN), Gilead Sciences Inc (NASDAQ: GILD) to name a few, that could drive up a takeout premium.

  • Price Action: MDGL shares are up 6.71% at $250.35 on the last check Tuesday.

Latest Ratings for MDGL

Date

Firm

Action

From

To

Oct 2021

Jefferies

Initiates Coverage On

Buy

Aug 2021

HC Wainwright & Co.

Maintains

Buy

May 2021

Canaccord Genuity

Maintains

Buy

View More Analyst Ratings for MDGL

廣告

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.